J3055 Injection talquetamab-tgvs 0.25 milligrams
J-Codes
Also known as: talquetamab, Tecvayli, bispecific T-cell engager
Talquetamab-tgvs (Tecvayli) 0.25 milligram injection is a bispecific T-cell engager monoclonal antibody used for the treatment of relapsed or refractory multiple myeloma.
Clinical Context
Indicated for relapsed/refractory multiple myeloma patients. Engages T-cells to target malignant plasma cells. Administered intravenously with careful monitoring for cytokine release syndrome and other immune-related adverse events.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.